Use of the TDT for Prevention of Anastomotic Leakage After Laparoscopic Anterior Resection for Rectal Cancer
Launched by THIRD MILITARY MEDICAL UNIVERSITY · Feb 18, 2016
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
Patients were randomly assigned to two groups, the TDT and non-TDT group after the laparoscopic LAR and DST procedure was decided during operation. Randomization was obtained through a computer-generated random number sequence allocation. Surgeon blinding was performed to ensure all the intraoperative decisions made by the surgeon were not interfered with by the grouping. All the operative procedures fully complied with the guideline for the diagnosis and treatment of colorectal cancer and the technique of total mesorectal excision (TME). The preservation of the left colonic artery was judg...
Gender
ALL
Eligibility criteria
- • Inclusion criteria: all consecutive 18 to 80 years old individuals diagnosed as primary rectal adenocarcinoma with the lower edge of the tumor less than 10 cm from the anal verge were considered eligible; with the classification of American Society of Anaesthesiologist (ASA) of I, II, or III; Laparoscopic LAR+ with double stapling technique (DST) was planned to perform for the patients. All the preoperative procedures should comply with the guideline for the diagnosis and treatment of colorectal cancer.
- • Exclusion criteria: The emergency operation for rectal cancer with obstruction, bleeding, or perforation would be excluded. Patients with inflammatory bowel disease (IBD), familial adenomatous polyposis (FAP), recurrent rectal cancer, or synchronous cancer would not be suitable. Patients with preoperative radiotherapy were excluded. Patients who underwent other types of surgeries for rectal cancer, including Hartmann's procedure, abdominoperineal resection (APR), intersphincteric resection ( ISR), et al. were excluded intraoperatively
About Third Military Medical University
Third Military Medical University is a leading medical research institution located in China, renowned for its commitment to advancing healthcare through innovative clinical research and education. With a strong emphasis on military and civilian health, the university integrates cutting-edge scientific methodologies and interdisciplinary collaboration to enhance patient outcomes. Its robust clinical trial framework supports a diverse range of studies, fostering the development of new therapeutic interventions and contributing to the global body of medical knowledge. Through rigorous ethical standards and a focus on translational research, Third Military Medical University aims to address critical health challenges and improve community health on both local and international levels.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chongqing, Chongqing, China
Patients applied
Trial Officials
Tong weidong, Professor
Principal Investigator
Daping Hospital, Third Military Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials